Endocrine Journal
Online ISSN : 1348-4540
Print ISSN : 0918-8959
ISSN-L : 0918-8959
Elevated Plasma Immunoreactive Neuropeptide Y Concentrations and Its Increased Urinary Excretion in Patients with Advanced Diabetic Nephropathy
CHIHARU SATOHFUMITOSHI SATOHKAZUHIRO TAKAHASHIOSAMU MURAKAMIMASAHIKO SONEKAZUHITO TOTSUNETAMAMI YABEMAKOTO OHNEDAMOTOJI FUKUDAKAZUHIKO SUGIMURASUSUMU OGAWAHIROTAKA NAGAKUBOTOKUTARO SATOTORAICHI MOURI
Author information
JOURNAL FREE ACCESS

1999 Volume 46 Issue 1 Pages 139-146

Details
Abstract

Neuropeptide Y (NPY) is a potent vasoconstrictor peptide that is abundant in the brain and the peripheral sympathetic nervous system. In the present study we investigated possible changes in plasma immunoreactive (IR)-NPY concentrations and urinary IR-NPY excretion in patients with non-insulin dependent diabetes mellitus (NIDDM) and the relationship to diabetic complications, such as nephropathy and neuropathy. IR-NPY in plasma and urine was measured by radioimmunoassay in 69 patients with NIDDM. Plasma IR-NPY concentrations in patients with advanced nephropathy (creatinine clearance <30ml/min) (100.5±10.3pmol/l, n=9, mean±SEM) were higher than in the control subjects (55.0±6.8 pmol/l, n=15) (P<0.02). Urinary excretion of IR-NPY and fractional excretion of NPY were also increased in the patients with advanced nephropathy. Sephadex G-50 column chromatography of the urine extracts obtained from healthy subjects, diabetic patients with renal failure and non-diabetic patients with renal failure showed an immunoreactive peak eluting in the NPY position. On the other hand, neither plasma nor urinary IR-NPY was high in patients with retinopathy, or in patients with peripheral neuropathy. The present study has, for the first time, shown high plasma IR-NPY concentrations and urinary IR-NPY excretion in NIDDM patients with advanced nephropathy.

Content from these authors
© The Japan Endocrine Society
Previous article Next article
feedback
Top